ATE293630T1 - Combretastatine a-4 phosphate prodrug salze mit stickstoff-enthaltenden verbindungen - Google Patents

Combretastatine a-4 phosphate prodrug salze mit stickstoff-enthaltenden verbindungen

Info

Publication number
ATE293630T1
ATE293630T1 AT01970806T AT01970806T ATE293630T1 AT E293630 T1 ATE293630 T1 AT E293630T1 AT 01970806 T AT01970806 T AT 01970806T AT 01970806 T AT01970806 T AT 01970806T AT E293630 T1 ATE293630 T1 AT E293630T1
Authority
AT
Austria
Prior art keywords
combretastatine
containing compounds
nitrogen containing
phosphate prodrug
prodrug salts
Prior art date
Application number
AT01970806T
Other languages
German (de)
English (en)
Inventor
John J Venit
Mandar V Dali
Manisha M Dali
Yande Huang
Charles E Dahlheim
Ravindra W Tejwani
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE293630T1 publication Critical patent/ATE293630T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01970806T 2000-09-14 2001-09-12 Combretastatine a-4 phosphate prodrug salze mit stickstoff-enthaltenden verbindungen ATE293630T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23256800P 2000-09-14 2000-09-14
US25192100P 2000-12-07 2000-12-07
PCT/US2001/028401 WO2002022626A1 (en) 2000-09-14 2001-09-12 Combretastatin a-4 phosphate prodrug salts with nitrogen-containing compounds

Publications (1)

Publication Number Publication Date
ATE293630T1 true ATE293630T1 (de) 2005-05-15

Family

ID=26926130

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01970806T ATE293630T1 (de) 2000-09-14 2001-09-12 Combretastatine a-4 phosphate prodrug salze mit stickstoff-enthaltenden verbindungen

Country Status (26)

Country Link
US (2) US6670344B2 (enExample)
EP (1) EP1320534B1 (enExample)
JP (2) JP4149804B2 (enExample)
KR (1) KR100858464B1 (enExample)
CN (1) CN100338077C (enExample)
AR (1) AR030727A1 (enExample)
AT (1) ATE293630T1 (enExample)
AU (2) AU785183B2 (enExample)
BR (1) BRPI0107210B1 (enExample)
CA (1) CA2422359C (enExample)
DE (1) DE60110249T2 (enExample)
EE (1) EE200200249A (enExample)
ES (1) ES2241872T3 (enExample)
HK (1) HK1052356B (enExample)
HU (1) HU229055B1 (enExample)
IL (3) IL149601A0 (enExample)
MX (1) MXPA03002209A (enExample)
NO (1) NO329973B1 (enExample)
NZ (1) NZ524926A (enExample)
PE (1) PE20020445A1 (enExample)
PT (1) PT1320534E (enExample)
RS (1) RS50309B (enExample)
SK (1) SK287117B6 (enExample)
TW (1) TWI250163B (enExample)
UY (1) UY26935A1 (enExample)
WO (1) WO2002022626A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019944D0 (en) * 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US20050153939A1 (en) * 2003-09-10 2005-07-14 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US7603190B2 (en) * 2001-04-19 2009-10-13 Sony Corporation Digital recording/reproducing apparatus
JP2004536847A (ja) * 2001-07-13 2004-12-09 オキシジーン， インコーポレイテッド 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US20090137687A1 (en) * 2003-02-28 2009-05-28 Oxigene, Inc. Compositions and Methods With Enhanced Therapeutic Activity
CN100365000C (zh) * 2003-09-18 2008-01-30 雍智全 Combretastatin A-4磷酰胆碱类前体药物以及其合成与应用
EP1696934B1 (en) 2003-12-23 2013-05-29 Schering-Plough Ltd. Florfenicol prodrug having improved water solubility
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
CA2611712C (en) 2005-06-14 2014-05-13 Baylor University Combretastatin analogs with tubulin binding activity
CN1907989B (zh) * 2005-08-02 2011-08-17 浙江天皇药业有限公司 毛兰素盐及其制备方法和包含其的药物组合物
CN101374801B (zh) * 2005-12-19 2014-07-02 梅特希尔基因公司 用于增强抗真菌剂活性的组蛋白脱乙酰酶抑制剂
US9504678B2 (en) 2006-04-04 2016-11-29 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an acid inhibitor
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
JP2010513326A (ja) 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
US20090012325A1 (en) * 2007-02-22 2009-01-08 Ajith Manage Methods for preparing phosphoric acids of combrestastatin and derivatives thereof
WO2008109076A1 (en) * 2007-03-02 2008-09-12 Oxigene, Inc. Methods for enhancing the efficacy of vascular disrupting agents
PL2170292T3 (pl) * 2007-06-22 2014-06-30 Bristol Myers Squibb Holdings Ireland Tabletkowane kompozycje zawierające atazanawir
CN101795674A (zh) * 2007-06-22 2010-08-04 百时美施贵宝公司 含有阿扎那韦的压片组合物
DE602008005462D1 (de) * 2007-06-22 2011-04-21 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
KR20100033378A (ko) * 2007-06-22 2010-03-29 브리스톨-마이어스 스큅 컴퍼니 아타자나비르를 함유하는 정제 조성물
JP5302328B2 (ja) 2007-11-21 2013-10-02 オキシジーン， インコーポレイテッド 造血性新生物を治療するための方法
CN102757338B (zh) * 2012-02-29 2015-02-25 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸氨基酸乙酯盐、制备方法及其用途
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
JP2018523712A (ja) 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018144910A1 (en) 2017-02-02 2018-08-09 Bioventures, Llc Methods of protecting against neurodegeneration
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
WO2025250885A1 (en) * 2024-05-31 2025-12-04 Oncotelic, Inc. In situ tumor-infiltrating lymphocyte therapeutics for cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
DE3438386A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Phosphorsaeurevinylbenzylester, ihre herstellung und verwendung
GB9106177D0 (en) 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
DE19506885A1 (de) 1995-02-17 1996-08-22 Schering Ag Neue Borneolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
WO1999035159A1 (en) * 1998-01-08 1999-07-15 Brigham & Women's Hospital, Inc. Lymphoma/leukemia oncogene, oncoprotein and methods of use
DE69942645D1 (en) * 1998-01-09 2010-09-16 Body Corporate Of The State Of Synthese von combretastatin a-4 prodrugs
GB9903403D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
GB0019944D0 (en) 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts

Also Published As

Publication number Publication date
RS50309B (sr) 2009-09-08
KR20020063187A (ko) 2002-08-01
SK6722002A3 (en) 2002-11-06
PE20020445A1 (es) 2002-05-18
HU229055B1 (hu) 2013-07-29
CN100338077C (zh) 2007-09-19
YU34802A (sh) 2005-07-19
HK1052356B (zh) 2008-06-27
EE200200249A (et) 2003-06-16
UY26935A1 (es) 2002-04-26
IL149601A0 (en) 2002-11-10
CA2422359A1 (en) 2002-03-21
NO329973B1 (no) 2011-01-31
HUP0204423A2 (en) 2003-05-28
US20040054212A1 (en) 2004-03-18
KR100858464B1 (ko) 2008-09-16
NO20022270L (no) 2002-07-01
US6670344B2 (en) 2003-12-30
EP1320534A1 (en) 2003-06-25
CN1392876A (zh) 2003-01-22
BRPI0107210B1 (pt) 2017-09-26
IL149601A (en) 2007-06-17
AU2007200218A1 (en) 2007-02-08
JP4149804B2 (ja) 2008-09-17
WO2002022626A8 (en) 2002-04-18
BR0107210A (pt) 2003-02-25
US20020072507A1 (en) 2002-06-13
DE60110249D1 (de) 2005-05-25
SK287117B6 (sk) 2009-12-07
NO20022270D0 (no) 2002-05-13
IL176088A0 (en) 2006-10-05
TWI250163B (en) 2006-03-01
NZ524926A (en) 2004-10-29
MXPA03002209A (es) 2004-03-02
ES2241872T3 (es) 2005-11-01
JP2004509128A (ja) 2004-03-25
AR030727A1 (es) 2003-09-03
AU9077101A (en) 2002-03-26
JP2008195740A (ja) 2008-08-28
PT1320534E (pt) 2005-08-31
US6855702B2 (en) 2005-02-15
AU785183B2 (en) 2006-10-19
EP1320534B1 (en) 2005-04-20
WO2002022626A1 (en) 2002-03-21
HK1052356A1 (en) 2003-09-11
HUP0204423A3 (en) 2005-02-28
CA2422359C (en) 2008-12-23
DE60110249T2 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
DE60110249D1 (de) Combretastatine a-4 phosphate prodrug salze mit stickstoff-enthaltenden verbindungen
DE60111734D1 (de) [1,4']-bipiperidin verbindungen
ATE432265T1 (de) Pyrimidinon verbindungen
EP1296698A4 (en) THERAPEUTIC AGENTS - II
ATE396720T1 (de) Glukokinase beeinflussende verbindungen
DK1294715T3 (da) Quinazolinditosylatsaltforbindelser
ATE283049T1 (de) Antibakterielle verbindungen
DE69927008D1 (de) Verbindungen mit kalzilytischer wirkung
DE50101049D1 (de) Ammoniumgruppen aufweisende organosiliciumverbindungen
NO20020030L (no) Krystallinske 1-metylkarbapenemforbindelser
DE69939378D1 (de) Antithrombotische verbindungen
NO20022948L (no) Delvis mettede kalsiumkanal-blokkeringsforbindelser
ATE384726T1 (de) Bicyclische heteroaromatische verbindungen
DE60131781D1 (de) Kalzilytische verbindungen
DE60228478D1 (de) Aryl-annellierte azapolyzyklische verbindungen
ATE423762T1 (de) Calcilytische verbindungen
NO20031837D0 (no) Kalsilytiske forbindelser
DE60024760D1 (de) Einlagerungsverbindung
NO20030416D0 (no) Krystallinsk terapeutisk forbindelse
DK1320534T3 (da) Combrestatin A-4-phosphat-prodrugsalte med nitrogenholdige forbindelser
ATE289302T1 (de) Heterozyklische verbindungen mit entzündungshemmender wirkung
DE69942494D1 (de) Verbindungen mit Wachstumshormon-freisetzender Eigenschaft
GB0011240D0 (en) Novel phosphorous compounds
SE0004458D0 (sv) Pharmaceutically useful compounds
SE0002922D0 (sv) Pharmaceutically useful compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1320534

Country of ref document: EP